Drug Profile
Research programme: recombinant protein therapeutics - Halozyme Therapeutics/BioAtla
Latest Information Update: 12 Nov 2019
Price :
$50
*
At a glance
- Originator BioAtla; Halozyme Therapeutics
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation; Skin disorders
- Discontinued Cancer